SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Cell Therapeutics (CTIC) -- Ignore unavailable to you. Want to Upgrade?


To: tom pope who wrote (617)3/16/2005 9:06:09 AM
From: Icebrg  Respond to of 946
 
Actually, the two previous transactions were not straight buys, but options excersizes (sp). Given his background and the number of boards he is presently on, he should have a fair idea about what he is doing.

The question is only why. He has as far as I know never bought stock from the market before. The size of the transaction most probably means this is like change for him. So, why bother at all buying 5000 shares?

Erik



To: tom pope who wrote (617)3/16/2005 12:46:23 PM
From: Sam Citron  Read Replies (1) | Respond to of 946
 
Tom,

Here's a table indicating how well insider buying predicted subsequent stock price increases in biotechs from 1996-2001. The exact specifications of the model are not indicated. And the author notes that the 2002 results were a disaster.

amazon.com

Sam



To: tom pope who wrote (617)5/2/2005 11:06:05 AM
From: manny_velasco  Respond to of 946
 
07:12 CTIC Cell Therapeutics announces Phase 3 results for Xyotax (3.85 )

Co announces the results of its phase III clinical studies of Xyotax in non-small cell lung cancer. Both trials demonstrated equivalent survival with significant reductions in serious side effects when compared to either docetaxel or gemcitabine/vinorelbine; although they missed their primary endpoints of superior overall survival.